What Is Tirzepatide? Understanding Mounjaro, Zepbound & the Dual-Action GLP-1

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide activates both GIP and GLP-1 receptors simultaneously, producing enhanced metabolic effects.

The medication is sold under two brand names. Mounjaro was approved by the FDA in May 2022 for the treatment of type 2 diabetes. Zepbound received FDA approval in November 2023 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

Tirzepatide is administered as a once-weekly subcutaneous injection and is available in multiple dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The dual-action mechanism has been studied extensively in clinical trials for anti-obesity treatment.

The innovation behind tirzepatide lies in its dual receptor activation. GLP-1 receptor agonism provides the appetite-suppressing and blood-sugar-lowering effects that are well established with medications like semaglutide. GIP receptor agonism adds an additional layer of metabolic benefit that enhances overall efficacy.

GIP (glucose-dependent insulinotropic polypeptide) is a hormone released from the small intestine after eating. It plays a key role in insulin secretion, fat metabolism, and energy balance. By activating GIP receptors, tirzepatide enhances insulin sensitivity in fat tissue, promotes more efficient fat burning, and may have direct effects on the brain's appetite regulation centers that complement GLP-1 signaling.

The combined activation of both pathways produces a synergistic effect. Preclinical studies suggest the dual mechanism leads to greater reductions in body fat percentage, improved lipid profiles, and more significant reductions in liver fat compared to GLP-1-only medications. This may explain why tirzepatide consistently produces greater weight loss in clinical trials.

The tirzepatide clinical trial program evaluated the medication for weight management in over 5,000 participants. Participants receiving the highest dose (15 mg) lost a substantial average share of their body weight over roughly 72 weeks — approaching one-quarter of their starting weight in the highest-dose group. Even the lowest dose produced meaningful average weight loss.

Trials that focused on patients with both obesity and type 2 diabetes showed clinically significant average weight loss at the highest dose, along with substantial A1C reductions.

A notable finding was the proportion of participants achieving clinically meaningful weight loss thresholds. A majority of participants on the highest dose lost at least one-fifth of their body weight, and a sizable subset lost a quarter or more. These outcomes were among the strongest observed in randomized controlled trials of weight-management pharmacotherapy.

Tirzepatide follows a gradual dose escalation to improve tolerability. Treatment begins at 2.5 mg weekly for four weeks, then increases to 5 mg. From there, increases of 2.5 mg can occur every four weeks based on individual response and tolerability, up to a maximum of 15 mg per week.

The injection is given once weekly using a single-dose prefilled pen. Common injection sites include the abdomen, thigh, or upper arm. Patients can rotate injection sites and choose any day of the week, as long as they maintain a consistent schedule. Most patients find the injection process quick and straightforward.

Appetite reduction typically begins within the first few weeks of treatment, even at the lowest dose. Clinically significant weight loss (5% or more of body weight) is usually achieved within the first two to three months. Peak weight loss generally occurs between 12 and 18 months. As with all GLP-1 medications, tirzepatide works best when combined with dietary modifications and regular physical activity.

Tirzepatide cost depends heavily on insurance status, the access pathway used, and the prescribed dose. Brand-name pricing without insurance is frequently cited as a barrier, so many patients explore insurance coverage, manufacturer savings programs, or telehealth subscriptions to keep ongoing treatment affordable.

Insurance coverage for tirzepatide is expanding but remains inconsistent. Most commercial plans cover Mounjaro for type 2 diabetes with prior authorization. Coverage for Zepbound (weight management) is more limited, though employer-sponsored plans are increasingly adding it. Eli Lilly offers a savings card program that can reduce out-of-pocket costs for eligible commercially insured patients.

At Weight Method, tirzepatide subscriptions start at $329 per month, including medication, physician oversight, and ongoing clinical support — with no insurance paperwork or pharmacy trips. Our medical team evaluates your health profile, BMI, and treatment goals to determine whether tirzepatide is the right choice for you, and the all-inclusive subscription covers your evaluation and ongoing dose management throughout treatment.